{"url_path":"/sec/avns/8-k/2026-07-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1606498/0001606498-26-000096-index.html","accession_number":"0001606498-26-000096","cik":"0001606498","ticker":"AVNS","issuer_name":"AVANOS MEDICAL, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1606498/0001606498-26-000096-index.html","primary_entity_key":"0001606498","primary_entity_name":"AVANOS MEDICAL, INC."},"word_count":447,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders\n\nOn July 22, 2026, Avanos Medical, Inc., a Delaware corporation (the “Company”), held a special meeting of stockholders (the “Special Meeting”) to vote on the proposals described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on June 10, 2026, as supplemented on July 14, 2026 (“the Proxy Statement”).\n\nAs of the close of business on June 18, 2026, the record date for the Special Meeting (the “Record Date”), there were 46,847,816 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), outstanding, each of which was entitled to one vote on each proposal at the Special Meeting. At the Special Meeting, a total of 35,207,549 shares of Common Stock, representing approximately 75.15% of the outstanding shares of Common Stock, were present in person or represented by proxy, constituting a quorum to conduct business.\n\nAt the Special Meeting, the Company’s stockholders voted on the following matters:\n\n1.A proposal to approve and adopt the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the “Merger Agreement”), by and among the Company, A-AV Holdco I, Inc., a Delaware corporation (“Parent”), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”), pursuant to which, among other things, Merger Subsidiary will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the “Merger”), and approve the consummation of the transactions contemplated by the Merger Agreement, including the Merger (“Proposal No. 1”);\n\n2.A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company’s named executive officers that is based on or otherwise relates to the Merger (“Proposal No. 2”); and\n\n3.A proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes cast at the Special Meeting to approve Proposal No. 1 (“Proposal No. 3”).\n\nThe final voting results for each proposal are described below. Proposal No. 3 was not submitted to the Company’s stockholders for approval at the Special Meeting because there were sufficient votes to approve Proposal No. 1. For more information on each of these proposals, see the Proxy Statement.\n\nProposal No. 1. The Company’s stockholders approved Proposal No. 1. The votes cast on Proposal No. 1 were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n35,119,79332,50855,248N/A\n\nProposal No. 2. The Company’s stockholders approved Proposal No. 2. The votes cast on Proposal No. 2 were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n30,620,3954,220,505366,649N/A"}